Miriam E. Tucker
June 21, 2021
The American Diabetes Association's "living" Standards of Medical Care in Diabetes have been updated with recent data from clinical trials regarding cardiovascular disease and chronic kidney disease in type 2 diabetes and delay of type 1 diabetes.
The updates are now available online in Diabetes Care.
Since 2018, the ADA's Standards of Care have been issued as a living document, meaning that they are updated online as new evidence arises or new products are approved, rather than just once every calendar year as in the past.
"There have been so many exciting advancements in the field of diabetes and that is why we are publishing more frequent updates to the Standards of Care," ADA chief scientific and medical officer Robert Gabbay, MD, said in a statement.
In the section addressing cardiovascular disease and risk management, new data have been included from several cardiovascular trials, including the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial (VERTIS CV), the Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED) trial, the Empagliflozin Outcome Trial in Patients With Chronic Heart Failure and a Reduced Ejection Fraction (EMPEROR-Reduced), and the Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trial.
The section on microvascular complications and foot care now includes data from trials of medication use in patients with chronic kidney disease, including Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD), first reported in August at the virtual European Society of Cardiology (ESC) 2020 Congress and subsequently published in the New England Journal of Medicine, and the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial.
And in the section on classification and diagnosis of diabetes, new information has been added from the trial showing that the anti-CD3 antibody teplizumab can delay the onset of type 1 diabetes in high-risk relatives of people who have the disease. An FDA advisory committee voted narrowly in May to recommend approval of teplizumab for this indication.